These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12461618)

  • 1. Ultrastructural features of highly active antiretroviral therapy-associated partial lipodystrophy.
    Lloreta J; Domingo P; Pujol RM; Arroyo JA; Baixeras N; Matias-Guiu X; Gilaberte M; Sambeat MA; Serrano S
    Virchows Arch; 2002 Dec; 441(6):599-604. PubMed ID: 12461618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sevastianova K; Sutinen J; Kannisto K; Hamsten A; Ristola M; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E85-91. PubMed ID: 18430964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Domingo P; Matías-Guiu X; Pujol RM; Domingo JC; Arroyo JA; Sambeat MA; Vázquez G
    J Infect Dis; 2001 Nov; 184(9):1197-201. PubMed ID: 11598845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sutinen J; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E687-92. PubMed ID: 17062843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipodystrophy in HIV 1-infected patients: lessons for obesity research.
    Villarroya F; Domingo P; Giralt M
    Int J Obes (Lond); 2007 Dec; 31(12):1763-76. PubMed ID: 17653062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis.
    Domingo P; Vidal F; Domingo JC; Veloso S; Sambeat MA; Torres F; Sirvent JJ; Vendrell J; Matias-Guiu X; Richart C;
    Eur J Clin Invest; 2005 Dec; 35(12):771-80. PubMed ID: 16313254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity.
    Villarroya F; Domingo P; Giralt M
    Trends Pharmacol Sci; 2005 Feb; 26(2):88-93. PubMed ID: 15681026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy.
    Giralt M; Domingo P; Guallar JP; Rodriguez de la Concepción ML; Alegre M; Domingo JC; Villarroya F
    Antivir Ther; 2006; 11(6):729-40. PubMed ID: 17310817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases].
    Tao MM; Zhang L; Qiu ZF; Xie J; Han Y; Yu W; Li M; Li TS
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):867-71. PubMed ID: 19671283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.
    Yki-Järvinen H; Sutinen J; Silveira A; Korsheninnikova E; Fisher RM; Kannisto K; Ehrenborg E; Eriksson P; Hamsten A
    Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):688-94. PubMed ID: 12615670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.
    Nolan D; John M; Mallal S
    Antivir Ther; 2001 Sep; 6(3):145-60. PubMed ID: 11808750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy.
    Johnson JA; Albu JB; Engelson ES; Fried SK; Inada Y; Ionescu G; Kotler DP
    Am J Physiol Endocrinol Metab; 2004 Feb; 286(2):E261-71. PubMed ID: 14532165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders?
    Cossarizza A; Mussini C; Viganò A
    Bioessays; 2001 Nov; 23(11):1070-80. PubMed ID: 11746223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
    Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
    Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy.
    Sutinen J; Kannisto K; Korsheninnikova E; Fisher RM; Ehrenborg E; Nyman T; Virkamäki A; Funahashi T; Matsuzawa Y; Vidal H; Hamsten A; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E941-9. PubMed ID: 14749206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
    Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
    Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 protease inhibitor-associated partial lipodystrophy: clinicopathologic review of 14 cases.
    Pujol RM; Domingo P; Xavier-Matias-Guiu ; Francia E; Sanbeat MA; Alomar A; Vazquez G
    J Am Acad Dermatol; 2000 Feb; 42(2 Pt 1):193-8. PubMed ID: 10642672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.